Why Zymeworks Stock Is Back In Focus After Q2 Results

Zymeworks (ZYME) is back on investor watch after reporting a second quarter net loss of US$45.02 million and outlining plans tied to a potential zanidatamab decision and the Theravance Biopharma acquisition.

The company also completed a share repurchase of 1,971,454 shares for US$49.4 million, equal to 2.7% of its stock, which adds another factor for you to consider when assessing Zymeworks today.

The latest results and guidance have arrived after a mixed stretch for Zymeworks. The share price is at US$25.12 with a 7 day share price return of 6.71% and a year to date share price return that is down 5.63%. The 1 year total shareholder return of 74.93% and 3 year total shareholder return of 238.54% point to investors already reacting strongly to the longer term pipeline story and recent milestones such as the completed buyback and the focus on zanidatamab and the Theravance Biopharma deal.

If you are weighing Zymeworks alongside other opportunities in healthcare, it can help to widen your watchlist with stocks exposed to similar themes. A good next step is to scan for differentiated healthcare AI and biotech exposures using the 42 healthcare AI stocks

The recent swing in Zymeworks stock sits at the crossroads of heavier reported losses and anticipation around zanidatamab and the Theravance deal. Is the latest move mainly sentiment, or a fair reflection of current value?

Most Popular Narrative: 36% Undervalued

The most followed narrative on Zymeworks pegs fair value at $39.23 per share compared with the last close at $25.12. That gap sits on a detailed set of growth and profitability assumptions that go well beyond the latest quarter.

The analysts have a consensus price target of $39.23 for Zymeworks based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $58.0, and the most bearish reporting a price target of just $28.0.

Want to understand why this fair value sits well above today’s price? The narrative leans on rapid revenue expansion, sharply improving margins, and a rich future earnings multiple. Curious which assumptions matter most and how they tie together in the model? The full story lays out the growth path behind that $39.23 figure.

Result: Fair Value of $39.23 (UNDERVALUED)

However, the Zymeworks story also hinges on partner milestones arriving as planned and early stage assets clearing clinical hurdles, so delays or trial setbacks could quickly challenge that undervalued narrative.

Another View: What Multiples Say About Zymeworks

The popular Zymeworks narrative points to a discounted fair value, yet the current P/S ratio of 48x is far higher than both the US Biotechs industry at 11.3x and peers at 10.5x. The fair ratio sits at just 0.1x, which signals meaningful valuation risk if sentiment cools.

Our DCF discussion is only one lens on Zymeworks. In contrast, this price to sales comparison gives a very different signal. The gap between today’s 48x and a fair ratio of 0.1x is wide. Which framework feels more realistic for your own expectations of this stock’s future cash generation and pricing power?

Next Steps

Curious whether the optimism in this Zymeworks discussion matches your own instincts. Take a closer look at the data, move quickly, and pressure test the 2 key rewards

Looking for more investment ideas beyond Zymeworks?

If Zymeworks has your attention, do not stop there. Use the Simply Wall Street screener to quickly surface other focused ideas that might fit your style.

• Target potential value opportunities by scanning companies that appear mispriced on quality and fundamentals through the 52 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks that show stronger balance sheets and fundamentals with the solid balance sheet and fundamentals stocks screener (51 results).
• Hunt for underfollowed opportunities by checking the screener containing 20 high quality undiscovered gems before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.